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Summary 
The binding of erythropoietin (EPO) to its receptor 
(EPO-R) activates the protein tyrosine kinase JAK2. 
The mechanism of JAK2 inactivation has been unclear. 
We show that the hematopoietic protein tyrosine phos- 
phatase SH-PTP1 (also called HCP and PTP1C) associ- 
ates via its SH2 domains with the tyrosine-phosphor- 
ylated EPO-R. In vitro binding studies suggest that 
Y429 in the cytoplasmic domain of the EPO-R is the 
binding site for SH-PTP1. Mutant EPO-Rs lacking Y429 
are unable to bind SH-PTP1; cells expressing such mu- 
tants are hypersensitive to EPO and display prolonged 
EPO-induced autophosphorylation of JAK2. Our re- 
sults suggest that activation of SH-PTP1 by binding 
to the EPO-R plays a major role in terminating prolifera- 
tive signals. 
Introduction 
Erythropoietin (EPO), a 34 kDa glycoprotein, is essential 
for the survival and proliferation of erythroid progenitor 
cells and their differentiation into erythrocytes. Like most 
receptors for hematopoietic growth factors, the EPO re- 
ceptor (EPO-R) (D'Andrea et al., 1989) is a type I trans- 
membrane protein and member of the cytokine receptor 
superfamily, which includes the receptors for granulocyte/ 
macrophage colony-stimulating factor, granulocyte col- 
ony-stimulatory factor, and the interleukins (ILs) IL-2, IL-3, 
IL-4, IL-5, IL-6, and IL-7. These receptors contain four con- 
served cysteines and a Trp-Ser-X-Trp-Ser motif in their 
extracellular domains (Cosman et al., 1990; Miyajima et 
al., 1992). The cytosolic domains of these receptors are 
dissimilar, and none contains intrinsic enzymatic activity. 
Nevertheless, binding of ligand induces rapid but transient 
tyrosine phosphorylation of a number of cellular proteins, 
including the receptors themselves; tyrosine phosphoryla- 
tion returns to basal levels after approximately 30 min (Mi- 
ura et al., 1991 ; Quelle and Wojchowski, 1991 ; Dusanter- 
Fourt et al., 1992; Linnekin et al., 1992). Thus, signaling 
through cytokine receptors is promoted by the activation 
of one or more protein tyrosine kinases (PTKs) and, pre- 
sumably, is terminated by one or more protein tyrosine 
phosphatases (PTPs). 
The PTK Janus kinase 2 (JAK2) has been strongly impli- 
cated in signal transduction by a number of cytokine recep- 
tors (Argetsinger et al., 1993; Witthuhn et al., 1993). Like 
JAK1, JAK3, and TYK2, the other members of the JAK 
family, JAK2 is composed of a C-terminal kinase domain, 
a kinase-like domain of unknown function, and an N-ter- 
minal -60 kDa segment (Firmbach-Kraft et al., 1990; 
Wilks et al., 1991; Takahashi and Shirasawa, 1994). The 
EPO-R associates with JAK2, and hormone binding to the 
EPO-R specifically, but transiently, increases JAK2 auto- 
phosphorylation and kinase activity (Witthuhn et al., 1993). 
In many growth factor receptors, phosphotyrosine (pY) 
residues serve as docking sites for proteins involved in 
downstream signal propagation. These secondary signal- 
ing molecules, such as phospholipase C7, rasGTPase- 
activating protein, and the regulatory subunit of phos- 
phatidylinositol 3-kinase, contain Src homology 2 (SH2) 
domains. SH2 domains comprise - 100 amino acids that 
selectively bind with high affinity to pY residues localized 
within specific amino acid sequences (reviewed by Cant- 
ley et al., 1991; Pawson and Gish, 1992; Schlessinger, 
1994). 
Although term ination of signals generated by PTKs most 
likely involves tyrosine dephosphorylation, little is known 
about which specific PTPs regulate these pathways. The 
identification of a subclass of nontransmembrane PTPs, 
which contain SH2 domains, suggested a role for these 
phosphatases in signaling from activated receptors. SH- 
PTP2 (Syp, PTP1 D, PTP2C), the homolog of the Drosoph- 
ila corkscrew-encoded protein, is ubiquitously expressed 
and binds via its SH2 domains to several growth factor 
receptors. Recent studies suggest that SH-PTP2 is a posi- 
tive signal transducer in some receptor PTK pathways (re- 
viewed by Sun and Tonks, 1994). 
Conversely, SH-PTP1 appears to be predominantly a 
negative regulator of growth factor signaling. Unlike SH- 
PTP2, SH-PTP1 is expressed predominantly in hemato- 
poietic cells, although it is also detected in some epithelial 
cells (Shen et al., 1991; Matthews et al., 1992; Plutzky et 
al., 1992; Yi et al., 1992). Several lines of evidence suggest 
that SH-PTP1 regulates multiple hematopoietic growth 
factor signaling pathways. SH-PTP1 is tyrosine phosphor- 
ylated upon stimulation of macrophages with colony- 
stimulating factor 1 (Yeung et al., 1992) and upon T cell 
receptor stimulation (Lorenz et al., 1994). SH-PTP1 has 
also been reported to associate with the IL-3 receptor 13 
chain (Yi et al., 1993) and the receptor PTK c-Kit (Yi and 
Ihle, 1993), but the specific SH-PTPl-binding site in these 
receptors has not been identified. Most importantly, muta- 
tions in the SH-PTP1 gene are the cause of the motheaten 
phenotype in mice (Shultz et al., 1993; Tsui et al., 1993). 
Mice harboring a SH-PTP1 null mutation (motheaten) or 
a deletion in the phosphatase domain of SH-PTP1 (moth- 
eaten viable) display a panoply of hematopoietic abnor- 
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Figure 1. Tyrosine Phosphorylation of Wild-Type and Mutant EPO-Rs 
Expressed in Ba/F3 Cells 
(A) Schematic diagram of mutant EPO-Rs. Open boxes ymbolize the 
extracellular nd intracellular domains of the EPO-R. Vertical lines in 
the extracellular domain represent conserved cysteine residues, and 
the closed box represents the WSXWS motif. The transmembrane 
domain (TM) is symbolized by a larger closed box. The mutant EPO-Rs 
are named either according to the amino acid position of the tyrosine 
(Y) exchanged to phenylalanine (F) or the last amino acid expressed 
in the deleted EPO-R. 
Abbreviation: wt, wild-type. 
(B) Wild-type (WT) and mutant EPORs are tyrosine phosphorylated 
upon ligand binding. Pools of approximately 1 x 107 Ba/F3 cells ex- 
pressing the indicated EPO-Rs were stimulated for 5 rain at 37°C with 
100 U of EPO/ml (plus sign) or were left unstimulated (minus ign). 
Detergent lysates were subjected to immunoprecipitation with anti- 
EPO-R (IP: (LEPOR) antiserum. The immunoprecipitates were sepa- 
rated by SDS-polyacrylamide g l electrophoresis and were analyzed 
by immunoblotting with the monoclonal nti-PTyr antibody 4G10 (blot: 
ePTyr). The positions of the tyrosine-phosphorylated wil -type (pY- 
EPOR) and 1-441 truncated EPO-R (pY-EPOR-t) are indicated with 
arrows. The positions of the protein molecular weight standards are 
indicated in kilodaltons (kDa). 
malities, indicating a central role for SH-PTP1 in the regu- 
lation of hematopoiesis. In the erythroid lineage, absence 
or reduction of enzymatic acitvity of SH-PTP1 results in 
hypersensitivity to EPO of EPO-responsive colony-form- 
ing unit-erythroid (CFU-E) precursor cells (Shultz and Sid- 
man, 1987; van Zant and Shultz, 1989). 
Here, we show that SH-PTP1 binds selectively to pY429 
in the cytoplasmic domain of the EPO-R. This interaction 
mediates the dephosphorylation and inactivation of JAK2. 
In a separate study, we have shown that an 11-amino acid 
peptide corresponding to the segment surrounding pY429 
directly activates the phosphatase activity of SH-PTP1 (D. 
Pei, U. L., U. K., B. G. N., and C. T. Walsh, submitted). 
Recruitment of SH-PTP1 to a segment of the EPO-R con- 
taining pY429, induced by EPO binding, causes dephos- 
phorylation of JAK2. Since stable expression of a mutant 
EPO-R lacking Y429 allows proliferation of cells in one-fifth 
to one-tenth the concentration of EPO required for cells 
expressing the wild-type EPO-R, we conclude that SH- 
PTPl-induced dephosphorylation of JAK2 is important for 
down-modulation of signals generated by the activated 
EPO-R. 
Results 
SH-PTP1 Associates with the EPO-R 
after EPO Addition 
To study proteins involved in EPO-R signaling, we ex- 
pressed the wild-type and mutant EPO-Rs in the pro-B cell 
line Ba/F3. In agreement with previous results (Miura et 
al., 1991; Quelle and Wojchowski, 1991), the addition of 
EPO to transfected cells expressing the wild-type EPO-R 
induced receptor phosphorylation on one or more tyrosine 
residues, as demonstrated by immunoblotting with the 
anti-pY monoclonal antibody 4G10 (anti-PTyr; Figure 1B, 
lanes 1 and 2). Tyrosine phosphorylation of the EPO-R is 
transient and returns to basal levels within 30 rain (Du- 
santer-Fourt et al., 1992; Linnekin et al., 1992), indicating 
that a pY phosphatase may be recruited to the receptor. 
Since SH-PTP1 is expressed in hematopoietic cells, in- 
cluding Ba/F3, we asked whether SH-PTP1 associates 
with the EPO-R. The coimmunoprecipitation experiments 
in Figure 2 show a specific interaction between EPO-R 
and SH-PTP1. Ba/F3 cells expressing the wild-type EPO-R 
were either stimulated for 5 min with 100 U/ml EPO 
or were left unstimulated. Detergent lysates of these'cells 
were prepared and used for immunoprecipitation experi- 
ments. Analysis of anti-SH-PTP1 immunoprecipitates by 
immunoblotting with anti-PTyr and reprobing with a poly- 
clonal antiserum against SH-PTP1 revealed a low basal 
level of tyrosine phosphorylation of SH-PTP1, unchanged 
upon EPO addition (Figure 2, lanes 1,3, and 4). In Ba/F3 
cells expressing the wild-type EPO-R and stimulated with 
EPO, the anti-SH-PTP1 antiserum also immunoprecipi- 
tated a tyrosine-phosphorylated protein, which migrated 
with an apparent molecular weight of 75 kDa (Figure 2, 
lane 4) and comigrated with the tyrosine-phosphorylated 
EPO-R (Figure 2, lane 6). To determine whether the 75 
kDa SH-PTP 1 -associated protein was the EPO-R, anti-SH- 
PTP1 immunoprecipitates from lysates of cells expressing 
the wild-type EPO-R and stimulated with EPO were treated 
with 1% SDS and were heat denatured. Upon reimmuno- 
precipitation with anti-EPO-R antiserum, the 75 kDa tyro- 
sine-phosphorylated protein could be detected by anti-PTyr 
immunoblotting (Figure 2, lane 5). Tyrosine-phosphory- 
lated SH-PTP1 was not recovered in the second immuno- 
precipitation, indicating that the association of SH-PTP1 
with the EPO-R was disrupted by the heat treatment. Sev- 
eral lines of evidence suggest that the 75 kDa tyrosine- 
phosphorylated protein complexed, after EPO addition, 
with SH-PTP1 is the tyrosine-phosphorylated EPO-R: it 
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Figure 2. SH-PTP1 Coirnmunoprecipitates with Wild-Type and 1-441 
Truncated EPO-R 
Control Ba/F3 cells (B) or cells expressing the wild-type (WT) or 
1-441 mutant EPO-R were stimulated with 100 U of EPO/ml (plus 
sign) for 5 min at 37°C or were left unstimulated (minus ign). Lysates 
from 1 x 107 cells were subjected to imrnunoprecipitation (IP)with 
antibodies against SH-PTP1 (~SHPTP1), EPO-R (~EPOR), or pre- 
immune serum (Preimrn.) from the same rabbit as the anti-EPO-R 
antibodies, as indicated above the panel. In lane 5, the sample was 
imrnunoprecipitated with an antibody against SH-PTP1, the immuno- 
precipitate was denatured ina solution containing SDS, and then it was 
reprecipitated with an antibody to the EPO-R. The im munoprecipitates 
were subjected to anti-PTyr immunoblot analysis (blot: aPTyr, top 
panel), and the filters were reprobed with an antibody to the EPO-R 
(blot: ~EPOR, middle panel) or to an anti-SH-PTP1 antiserum (blot: 
~SH-PTP1, lower panel). The positions of tyrosine-phosphorylated 
forms of the wild-type EPO-R (pY-EPOR~ 1-441 EPO-R (pY-EPOR-t), 
and SH-PTP1 (pY-SHPTP1) are indica'e by arrows. The band with 
the lowest gel mobility detected by anti-EP, oR i: nmunoblotting (middle 
panel) is not identical with the tyrosine-phcsphorylated EPO-R as it 
migrates faster than the tyrosine-phospho" bated EPO-R detected by 
anti-PTyr immunoblotting. Furthermore, the intensity of this particular 
band is not enhanced upon EPO stimulation. The positions of the 
protein molecular weight standards are indicated in kilodaltons (kDa). 
was reimmunoprecipitated with anti-EPO-R antiserum 
(Figure 2, lane 5); it was absent in the immunoprecipitation 
with preimmunserum (lane 7) and absent from the anti-SH- 
PTP1 immunoprecipitate from extracts of parental Ba/F3 
cells (lane 3); and it was reduced in size upon deletion of 
the 40 C-terminal amino acids of the EPO-R (lanes 10 
and 11). The tyrosine-phosphorylated EPO-R could not be 
detected directly by immunoblotting with our anti-EPO-R 
antiserum (Figure 2, compare blots of ~PTyr and aEPOR). 
One reason for this finding is that the sensitivity of the 
anti-PTyr monoclonal antibody is greater than that of our 
anti-EPO-R antibodies. Another is that only a small fraction 
of the EPO-R molecules, approximately 1000 receptors 
per cell, is present at the cell surface. 
Thus, in response to EPO, the wild-type EPO-R be- 
comes tyrosine phosphorylated and forms a complex with 
SH-PTP1. SH-PTP1 was not detected in anti-EPO-R im- 
munoprecipitates (Figure 2, lane 6; data not shown), prob- 
ably because only a small fraction of the tyrosine- 
phosphorytated EPO-R associates with SH-PTP1 at any 
given time. These experiments did not determine whether 
unphosphorylated EPO-R, before EPO addition, is com- 
plexed with SH-PTP1. However, the finding (below) that 
SH-PTP1 binding requires a specific pY in the EPO-R and 
is mediated by the SH2 domains of SH-PTP1 makes this 
unlikely, suggesting that SH-PTP1 associates with the 
EPO-R only after ligand-induced tyrosine phosphorylation 
of the receptor. 
pY429 in the Cytoplasmic Domain of the EPO-R 
Mediates Binding of SH-PTP1 
To determine which amino acid in the cytosolic domain 
of the EPO-R is responsible for binding SH-PTP1, we gen- 
erated a panel of EEPO-R deletion and tyrosine-to-phenyla- 
lanine point mutants, shown schematically in Figure 1A. 
To obtain stable cell lines, normally IL-3-dependent Ba/F3 
cells were transfected with plasmids harboring the altered 
EPO-R cDNAs. Pools of cells were selected initially in 
G418 and IL-3. Each of these EPO-R mutants gave rise 
to comparable number of cell pools that were able to grow 
with EPO as the sole added g rowth factor (data not shown). 
Thus, none of the altered tyrosine residues nor the C-ter- 
minal - 100 amino acids of the EPO-R was essential for 
the generation of a proliferative signal in Ba/F3 cells. 
Immunoprecipitation f cell lysates with anti-EPO-R anti- 
serum, followed by anti-PTyr immunoblotting showed that 
all of the mutant receptors tested in this experiment be- 
came tyrosine phosphorylated after EPO addition (see Fig- 
ure 1B, lanes 4, 6, 8, 10, and 12; compare with lane 2). 
EPO-induced tyrosine phosphorylation of the C-terminal 
deletion mutant 1-374 could not be detected (data not 
shown). All point mutants except Y429,431F generated a 
tyrosine-phosphorylated EPO-R with the same gel mobility 
as the wild-type EPO-R. Reproducibly, the tyrosine- 
phosphorylated mutant Y429,431F migrated as a diffuse 
species, somewhat slower than did the wild-type EPO-R 
(see Figure 1B, lanes 4 and 6). The altered gel mobility 
could be due to tyrosine phosphorylation on new sites, 
higher occupancy of the same sites phosphorylated inthe 
wild-type EPO-R, or both, Of the 8 tyrosine residues in the 
EPO-R cytoplasmic domain, 4 are deleted in the C-ter- 
minal truncated mutant EPO-R 1-441. Nonetheless, this 
receptor also becomes tyrosine phosphorylated (see Fig- 
ure 1B, lanes 11 and 12). That all of the mutant receptors 
containing tyrosine-to-phenylalanine mutations or a dele- 
tion of the C-terminal 40 amino acids became tyrosine 
phosphorylated after EPO addition suggested either that 
we have not altered the target yrosine for phosphorylation 
or, more likely, that the cytosolic domain of the EPO-R 
has multiple tyrosine-phosphorylation sites. 
The finding that SH-PTP1 associates with tyrosine- 
phosphorylated wild-type EPO-R suggested that one or 
more tyrosine residues in the cytosolic domain of the 
EPO-R could be crucial for binding. The ability of the mu- 
tant EPO-Rs to form a complex with SH-PTP1 was ana- 
lyzed by coimmunoprecipitation. I  Ba/F3 cells expressing 
EPO-R 1-441, a tyrosine-phosphorylated protein of ap- 
proximately 68 kDa (Figure 2, lane 10) coimmunoprecipi- 
tated with SH-PTP1. This protein represented the truncated 
1-441 EPO-R because of the following: it comigrated with 
the tyrosine-phosphorylated EPO-R 1-441 (Figure 2, lane 
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Figure 3. Mutation of Tyrosine Residues 429 and 431 to Phenylala- 
nine in the Cytoplasmic Domain of the EPO-R Abolishes Association 
with SH-PTP1 
Parental Ba/F3 cells and Ba/F3 cells expressing wild-type (WT) or 
mutant EPO-Rs (Y429,431F and Y460,464F) were incubated with 
100 U of EPO/ml for 5 rain at 37°C and were then lysed. Immunoprecip- 
itates (IPs) of the lysates with antibodies against EPO- R (aEPOR, lanes 
1-4) or SH-PTP1 (~SHPTP1, lanes 5-8) were analyzed by anti-PTyr 
immunoblotting. In lanes 9 and 10, anti-SH-PTP1 immunoprecipitates 
of lysates of Ba/F3 cells expressing the wild-type (WT) EPO-R (as in 
lane 5) were boiled in 50 p_l of 1% SDS, diluted 10-fold with 1 x lysis 
buffer, and incubated with a mixture of EPO-R antibodies raised 
against N- and C-terminal EPO-R peptides (lane 9,~EPOR) or preim- 
mune serum (Preimm., lane 10). These immunoprecipitates were ana- 
lyzed by anti-PTyr immunoblotting. The positions of the tyrosine- 
phosphorylated EPO-R (pY-EPOR) and tyrosine-phosphorylated 
SH-PTP1 (pY-SHPTP1) are marked with arrows. To show theequal 
efficiency of immunoprecipitation, the blots were either reprobed with 
anti-EPO-R antiserum (lanes 1-4) or anti-SH-PTP1 antiserum (lanes 
5-10), as indicated beneath the panels. The positions of unphosphory- 
lated EPO-R (EPOR) and SH-PTP1 (SHPTP1) are indicated with 
arrows. 
11); it was not precipitated from parental Ba/F3 cells or 
cells expressing the wild-type EPO-R (lanes 3 and 4); and it 
was absent in immunoprecipitates with preimmune serum 
(lane 8). The C-terminal 40 amino acids of the EPO-R thus 
are not required for interaction with SH-PTPI. This result 
eliminates the four tyrosine residues in the C-terminal seg- 
ment as essential docking sites for SH-PTPI. 
Similar experiments showed that the tyrosine-phos- 
phorylated forms of all of the EPO-Rs with point mutations, 
except for Y429,431 F and Y429F, become complexed with 
SH-PTP1 after EPO addition (Figure 3; data not shown). 
Proteins from lysates of EPO-stimulated cells were immu- 
noprecipitated either with anti-SH-PTP1 (Figure 3, lanes 
5-8) or anti-EPO-R antibodies (lanes 1-4) and were ana- 
lyzed by anti-PTyr immunoblotting. The mutant receptors 
Y429,431F and Y460, 464F were tyrosine phosphorylated 
o~EPOR GST-N+C-SH2 GST-N-SH2 GST 
105-- 
~-- pY-EPOR 
70-- 
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Figure 4. The SH2 Domains of SH-PTP1 Selectively Bind to PY429 
in the Cytosolic Domain of the EPO-R 
Parental Ba/F3 cells or BedF3 cells expressing the wild-type (WT); 
Y429,431 F; Y431 F; or Y460,464F EPO-Rs were incubated with 100 U 
of EPO/ml for 3 rain at 37°C and were then lysed. In lanes 1-5, the 
lysates were subjected to immunoprecipitation with an antiserum 
against the EPO-R (~EPOR). The lysates were incubated with GST- 
fusion proteins containing both SH-PTP1 SH2 domains (GST-N- 
C-SH2, lanes 6-10), the N-terminal SH2 domain (GST-N-SH2, lanes 
11-15), or GST alone (lanes 16-20). The immunoprecipitated or com- 
plexed proteins were analyzed by SDS-polyacrylamide g l electropho- 
resis and anti-PTyr immunoblotting ((~PTyr). 
to similar extents as was the wild-type EPO-R (Figure 3, 
lanes 1-3). However, only the tyrosine-phosphorylated 
wild-type and Y460, 464F receptors coimmunoprecipi- 
tated with SH-PTP1 (Figure 3, lanes 5-8). The single point 
mutant EPO-R Y429F, like the double point mutant 
Y429,431F, did not associate with SH-PTP1 (data not 
shown). Since the Y431 F receptor became tyrosine phos- 
phorylated (see Figure 1B, lane 8) and complexed with 
SH-PTP1 after EPO addition, although itwas reproducibly 
less than half as efficient as the wild-type receptor (see 
below; data not shown), these results suggest that Y429 
becomes phosphorylated after EPO addition and serves 
as the docking site for an SH2 domain in SH-PTP1. 
SH-PTP1 Binds via Its SH2 Domains to the EPO-R 
To investigate whether the SH2 domains of SH-PTP1 me- 
diate binding to the EPO-R, glutathione S-transferase- 
fusion (GST-fusion) proteins containing both SH2 do- 
mains of SH-PTP1 (GST-N-C-SH2) or only the N-terminal 
SH2 domain (GST-N-SH2) were produced in bacteria, 
bound to glutathione-agarose beads, and incubated with 
lysates from EPO-stimulated Ba/F3 cells expressing wild- 
type EPO-R or EPO-R mutants. Bound tyrosine-phosphor- 
ylated proteins were revealed by anti-PTyr immunoblotting 
(Figure 4, lanes 6-15). Control immunoprecipitations from 
the same lysates using the anti-EPO-R antibody and anti- 
PTyr immunoblotting revealed that, as before, all recep- 
tors were tyrosine phosphorylated to a similar extent after 
EPO addition (Figure 4, lanes 1-4). The wild-type EPO-R 
bound specifically to GST-N-C, but not o GST alone (Fig- 
ure 4, lanes 6 and 16). Mutation of EPO-R Y461 or Y464 
had no effect on GST-N-C binding (Figure 4, lane 9). How- 
ever, the double point mutant Y429,Y431F did not bind 
to GST-N-C, suggesting that either Y429, ¥431, or both 
were required for binding. Since the point mutant Y431F 
bound to GST-N-C (Figure 4, lane 8), we conclude that 
Y429 is the major binding site for SH-PTP1 on the EPO-R. 
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Figure 5. Binding of SH-PTP1 to the EPO-R 
Causes Dephosphorylation f JAK2 
(A) 32D cells expressing the wild-type (wt) 
EPO-R or EPO-R mutants Y429,431F or 1-374 
were incubated at 37°C with 100 U of EPO/ml 
for 0, 5, 15, 30, 45, or 60 min. The cells were 
lysed and incubated with an antiserum specific 
for JAK2 (~JAK2). The immunoprecipitates 
were analyzed by anti-PTyr immunoblotting 
0zPTyr, left panel) and by reprobing the blot 
with anti-JAK2 antiserum (aJAK2, right panel), 
as indicated above the panels. 
(B) Quantitation ofthe relative extent of JAK2 
phosphorylation after EPO addition (see A). 
The amount of tyrosine-phosphorylated JAK2, 
as assessed by densitometric s anning (arbi- 
trary units) was normalized to the similarly 
quantitated amount of JAK2 recovered in each 
immunoprecipitate. The very small amount of 
tyrosine-phosphorylated JAK2 present before 
EPO addition (0 rain) was substracted as back- 
ground. 
The same qualitative pattern of selective binding was ob- 
tained with the GST-fusion protein containing only the 
N-terminal SH-PTP1 SH2 domain (Figure 4, lanes 11-15). 
However, the amount of tyrosine-phosphorylated EPO-R 
bound to GST-N-SH2 was much lower. The N-terminal 
SH-PTP1 SH2 domain without he C-terminal SH2 domain 
could have a reduced affinity for tyrosine-phosphorylated 
Y429, or the N-terminal SH2 domain of SH-PTP1, when 
expressed without the other SH2 domain, might be im- 
properly folded. Thus, the N-terminal SH2 domain of SH- 
PTP1 is sufficient to bind specifically the tyrosine-phos- 
phorylated cytosolic domain of the wild-type EPO-R. 
Taken together with the data in Figures 2 and 3, these 
results show that the SH2 domains of SH-PTP1 mediate 
binding to pY429 in the cytosolic domain of the EPO-R. 
Recruitment of SH-PTP1 to the EPO-R Causes 
Dephosphorylation of JAK2 
In a separate study (D. Pei, U. L., U. K., B. G. N., and 
C. T. Walsh, submitted), we showed that a pY-containing 
peptide corresponding to the sequence surrounding Y429 
in the EPO-R directly bound to the N-terminal SH2 domain 
of SH-PTP1 and activated its enzymatic activity. Thus, 
binding of SH-PTP1 to the activated EPO-R would be ex- 
pected to localize SH-PTP1 adjacent to possible targets 
for dephosphorylation. One obvious potential target is 
JAK2 as it becomes transiently tyrosine phosphorylated 
after EPO addition (Witthuhn et al., 1993). 
Binding of SH-PTP1 to the EPO-R causes dephosphory- 
lation of JAK2, as shown by the experiments in Figures 
5A and 5B. For these experiments and the proliferation 
experiments described below, we expressed the wild-type 
EPO-R and the EPO-R mutants in the myeloid cell line 
32D. Unlike Ba/F3 cells, which are aneuploid and can 
spontaneously give rise to factor-independent variants, 
parental 32D cells are diploid and rigorously IL-3 depen- 
dent (Migliaccio et al., 1989). Although Ba/F3 cells facili- 
tate biochemical studies of the EPO-R, cell lines like 32D 
might reflect the in vivo situation more closely. 32D cells 
expressing either the wild-type EPO-R or the EPO-R mu- 
tants Y429,431F or 1-374 were lysed at various times 
after EPO addition and then were subjected to anti-JAK2 
immunoprecipitation, followed by anti-PTyr immunoblot- 
ting (Figure 5A, left panel). As a control for equal recovery 
of JAK2 in the immunoprecipitates, the blot was reprobed 
with anti-JAK2 antiserum (Figure 5A, right panel). In cells 
expressing the wild-type EPO-R, tyrosine phosphorylation 
of JAK2 was maximal at 5 min after EPO addition and 
then declined, reaching basal levels 45 min poststimula- 
tion (Figure 5A, ~zPTyr, upper panel). In contrast, in cell 
pools expressing the mutant EPO-R Y429,431F or the 
truncated EPO-R 1-374, the extent of JAK2 phosphoryla- 
tion was enhanced, and phosphorylation persisted for at 
least 60 min after EPO addition (Figure 5A, ~PTyr; middle 
and lower panels, respectively). Quantitation of these re- 
sults (Figure 5B) revealed that the half-life of JAK2 tyrosine 
phosphorylation in cells expressing the wild-type EPO-R 
was approximately 18 rain. In contrast, in two independent 
cell pools expressing the Y429,431F EPO-R, tyrosine 
phosphorylation ofJAK2 was only marginaly reduced from 
the maximum value after 60 rain of EPO treatment. Thus, 
binding of SH-PTP1 to the cytosolic domain of the EPO-R 
and its presumed subsequent activation, processes abro- 
gated by the Y429,431F mutation or a deletion encom- 
passing these residues, are required for prompt dephos- 
phorylation of JAK2. 
32D Cells Expressing an EPO-R Unable to Bind 
SH-PTP1 Are Hypersensitive to EPO 
To assess the role of SH-PTP1 in regulating proliferative 
signals generated by the EPO-R, we measured the prolif- 
eration of 32D cells expressing wild-type EPO-R or EPO-R 
Y429,431F. All cell pools analyzed showed comparable 
growth rates in IL-3 and expressed the same number of 
cell-surface EPO-Rs (data not shown). When grown in 
EPO, the half-maximal proliferation of pools of 32D cells 
expressing the wild-type EPO-R required 0.25 U of EPO/ml 
and maximal proliferation required about 1 U/ml (Figure 6). 
In contrast, although proliferation of EPO-R Y429,431F- 
expressing cells remained EPO dependent, 6 of 6 inde- 
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Figure 6. EPO-Dependent Proliferation of 32D Cells Expressing the 
Wild-Type EPO-R and the EPO-R Mutant Y429,431F 
The graph shows the proliferation ofI representative out of 6 indepen- 
dent cell pools expressing the wild-type EPO-R or the EPO-R mutant 
Y429, 431 F, in the presence of 0-5 U of EPO/ml measured by [3H]thym- 
idine incorporation. Each data point represents the mean ± SD of 
triplicate determinations• 
Abbreviation: cpm, counts per minute. 
pendent cell pools expressing the mutant receptors dis- 
played a leftward shift in their EPO dose-response curve. 
Pools of 32D cells expressing the mutant EPO-R 
Y429,431F achieved half-maximal proliferation in as little 
as 0.025 U of EPO/ml, reaching a maximum rate at 0.1 
U of EPO/ml (Figure 6). At the highest EPO concentrations 
employed, the rate of proliferation of cell pools expressing 
the wild-type EPO-R or the EPO-R mutant Y429,431F was 
the same. Thus, expression of an EPO-R unable to bind 
SH-PTP1 allows cells to proliferate in one-fifth to one-tenth 
the normal amount of EPO, indicating that the recruitment 
of SH-PTP1 to the EPO-R is important for down-modula- 
tion of intracellular signaling through the EPO-R. 
Discussion 
Binding of ligand to members of the cytokine receptor su- 
perfamily induces the tyrosine phosphorylation of several 
proteins, including the receptors themselves• Since phos- 
phorylation is transient, presumably PTPs cause protein 
dephosphorylation and signal termination. We have iden- 
tifed the first high affinity binding site for a specific PTP 
within the cytoplasmic domain of a cytokine receptor: SH- 
PTP1 specifically binds, via its SH2 domains, to a phos- 
phorylated peptide containing Y429 in the cytoplasmic do- 
main of the EPO-R. This association requires binding of 
EPO to the receptor, indicating that SH-PTP1 is selectively 
recruited to the activated signaling complex. Binding of 
SH-PTP1 to pY429 activates SH-PTP1 enzymatic activity 
(D. Pei, U. L., U. K., B. G. N., and C. T. Walsh, submitted) 
and causes dephosphorylation and inactivation of JAK2. 
Studies in which JAK2, SH-PTP1, and SH-PTP2 were ex- 
pressed in insect cells revealed that coexpression of SH- 
PTP1, but not its close relative SH-PTP2, leads to specific 
JAK2 dephosphorylation and inactivation of its kinase ac- 
tivity (data not shown). Most importantly, activation of SH- 
PTP1 by binding to the EPO-R is essential for appropriate 
down-modulation of intracellular proliferative signals since 
cells expressing mutant EPO-Rs that are unable to bind 
SH-PTP1 (Y429,431F and 1-374) display prolonged JAK2 
activation. This allows such cells to proliferate in one-fifth 
to one-tenth the concentration of EPO required for cells 
expressing the wild-type EPO-R. Experiments are in prog- 
ress to address whether cells expressing the single point 
mutant EPO-R Y429F display the same kinetics of JAK2 
dephosphorylation and EPO hypersensitivity as do cells 
harboring the double point mutant EPO-R Y429,431F. 
The binding specificity of the SH2 domains of SH-PTP1 
has been an open question. In vitro binding studies using 
a degenerate phosphotyrosyl peptide library showed that 
the SH2 domains of SH-PTP1 bind to phosphopeptides 
with the general sequence motif pY-hydrophobic-XXX- 
hydrophobic, in which XXX can be any amino acid. The 
preferred amino acid at positions +1 and +3 in the target 
sequence for the SH-PTP1 SH2 domains was reported to 
be phenylalanine (Songyang et al., 1994). According to 
this prediction, upon phosphorylation, 5 of the 8 tyrosine 
residues in the cytosolic domain of the EPO-R (residues 
Y343, Y401, Y429, Y431, and Y479) might bind SH-PTPI. 
Here, we measured the association of SH-PTP1 with 
wild-type and mutant EPO-Rs expressed in transfected 
Ba/F3 cells as well as the association in vitro of purified 
SH2 domains of SH-PTP1 with the tyrosine-phosphor- 
ylated cytosolic domains of wild-type and mutant EPO-Rs. 
Both studies showed that Y429 in the EPO-R is essential 
for binding to SH-PTP1. Using synthetic peptides, we 
showed that only pY429, in the sequence pY-Leu-Tyr- 
Leu-VaI-Val, is capable of binding SH-PTP1. A phospho- 
peptide containing the sequence corresponding to this 
segment of the EPO-R specifically binds the N-terminal 
SH2 domain of SH-PTP1 and activates its phosphatase 
activity (D. Pei, U. L., U. K., B. G. N., and C. T. Walsh, 
submitted). The binding affinity of phosphopeptides de- 
rived from the IL-3 receptor 13 chain and the IL-2 receptor 
13 chain to the N-terminal SH2 domain of SH-PTP1 was 
at least 5-fold lower (D. Pei, U. L., U. K., B. G. N., and 
C. T. Walsh, submitted). Since the Y431F mutant EPO-R 
bound to the SH2 domains of SH-PTP1 about half as effi- 
ciently as did the wild type EPO-R, it is possible that, phos- 
phorylated or unphosphoryiated, Y431 participates in 
binding to the SH2 domains• By analogy with results of 
phosphotyrosyl peptide competition assays performed on 
SH-PTP2 (Case et al., 1994) and the recent solution of 
the crystal structure of the SH-PTP2 N-terminal SH2 do- 
main (Lee et al., 1994), it is likely that the affinity of the 
SH-PTP1 SH2 domains for phosphotyrosyl peptides is 
also influenced by the amino acid residues at the +4 and 
+5 positions from the target pY. We have not yet studied 
the role of these residues (433 and 434) in the EPO-R. 
Interestingly, other cytokine receptors reported to form 
complexes with SH-PTP1 (e.g., c-Kit and the IL-3 receptor 
13 chain) contain sequnces resembeling the SH-PTP1- 
binding site in the EPO-R. 
Identification of the SH-PTPl-binding site on the EPO-R 
allowed us to examine the physiological role of association 
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of SH-PTP1 with the EPO-R. At least one function of recep- 
tor-associated SH-PTP1 appears to be the dephosphoryla- 
tion and inactivation of JAK2. Most likely, JAK2 is a direct 
substrate of SH-PTP1, a contention supported by the re- 
sults of our insect cell reconstitution studies (data not 
shown). Our results thus identify the first PTK substrate 
of a nontransmembrane PTP. Previous studies have es- 
tablished that the transmembrane PTPs CD45 (Ledbetter 
et al., 1993) and HPTPa (den Hertog et al., 1993) dephos- 
phorylate the negative regulatory tyrosines of members 
of the Src subfamily of nontransmembrane PTKs, resulting 
in PTK activation. Conversely, SH-PTPl-mediated de- 
phosphorylation of JAK2 results in JAK2 inactivation. 
Moreover, Janus-type kinases are not the only non- 
transmembrane PTKs that are negatively regulated by SH- 
PTP1. Recently, we found that activation of the Src family 
member Lck is prolonged upon thymocyte activation in 
motheaten mice (U. L., K. Ravichandran, S. Burakoff, and 
B. G. N., unpublished data). 
Binding of SH-PTP1 to other cytokine receptors proba- 
bly would have similar consequences. As the IL-3 receptor 
13 chain has been reported to activate JAK2 (Silvennoinen 
et al., 1993) and to associate with SH-PTP1 (Yi et al., 
1993), it is likely that signaling through this receptor is 
regulated in a similar fashion as is the EPO-R. Yi et al. 
(1993) reported that DA-3 cells with decreased SH-PTP1 
protein levels, due to the expression of antisense SH- 
PTP1 RNA, show hyperphosphorylation of the the IL-3 
receptor 13 chain and a slight increase in proliferation in 
response to IL-3. They suggested that the IL-3 receptor 
chain is a direct SH-PTP1 target. However, in the context 
of our results, it is unclear whether the IL-3 receptor 13 chain 
hyperphosphorylation bserved by these researchers was 
due to decreased dephosphorylation by SH-PTP1 or in- 
stead was a secondary consequence of prolonged JAK2 
activation. It will be important o determine whether SH- 
PTP1 dephosphorylates one or more of these sites. Fur- 
thermore, it should be noted that, whereas Yi et al. (1993) 
studied the effect of decreasing the total level of SH-PTP1 
expression within a cell, our studies focus on the specific 
role of receptor-bound SH-PTPI. This may account for 
the profound enhancement of cytokine sensitivity we have 
observed. 
Cells expressing EPO-Rs incapable of SH-PTP1 binding 
manifest prolonged JAK2 activation. As JAK2 is believed 
to be crucial for the generation of a proliferative signal by 
the EPO-R (Witthuhn et al., 1993), we speculated that the 
extended activity of JAK2 would alter the growth properties 
of these cells. Indeed, such cells proliferate in EPO con- 
centrations 5-fold to 10-fold lower than the 0.5-1.0 U/ml 
of EPO normally required for proliferation of cells express- 
ing the wild-type EPO-R. The notion that abnormal JAK2 
regulation and hyperproliferation are causally related is 
supported by recent studies in Drosophila. A mutation in 
the hopscotch locus, which encodes a JAK homolog, that 
generates a constitutively active JAK results in hematopoi~ 
etic tumors (Hanratty and Dearolf, 1993). 
Our results provide a molecular explanation for the hy- 
persensitivity of erythroid precursor cells to EPO observed 
in two genetic syndromes. In mice, a central role for SH- 
PTP1 in EPO-R signaling was suggested by studies of 
mice that either lack SH-PTP1 (motheaten) or are impaired 
in SH-PTP1 phosphatase activity (motheaten viable). The 
CFU-E erythroid progenitors from these mice are stimu- 
lated by lower than normal concentrations of EPO, and 
there are increased numbers of splenic CFU-Es in vivo 
(van Zant and Shultz, 1989). A possible explanation for 
these observations is that occupancy by EPO of fewer 
than normal cell surface EPO-Rs is sufficient o generate 
a proliferative signal and that SH-PTP1 is an important 
down-modulator of EPO-R signaling. However, it was also 
conceivable that the enhanced sensitivity of motheaten 
CFU-Es to EPO results from dysregulation of another sig- 
nal transduction pathway that served to lower the thresh- 
old for EPO-R stimulation. Our results clearly suggest that 
SH-PTP1 is a direct regulator of EPO-R signaling. 
Members of a large Finnish family with autosomal domi- 
nant benign erythrocytosis have a mutation in one allele 
of the EPO-R, which introduces a premature stop codon 
and generates an EPO-R lacking the C-terminal 70 amino 
acids (de la Chapelle et al., 1993). This deleted segment 
includes the binding site for SH-PTP1 that we have defined 
in the murine EPO-R. The only pathophysiologic manifes- 
tation of this trait is a high hematocrit and a corresponding 
increase in the concentration of hemoglobin in the blood. 
Similar to the erythroid progenitors from motheaten mice, 
cultured erythroid progenitors from these patients are 
stimulated by lower than normal concentrations of EPO. 
The inability of SH-PTP1 to bind to the truncated EPO-R 
or to be activated could account for the enhanced respon- 
siveness of these cells to EPO. Therefore, it will be of great 
interest to address whether polycythemia syndromes are 
also caused by an alteration in the EPO-R or by an impair- 
ment of SH-PTP1 or its regulation. 
Our results suggest a model for regulation of members 
of the JAK family of PTKs (Figure 7). We hypothesize that 
SH-PTP1, like SH-PTP2 (Sugimoto et al., 1993; Dechert 
et al., 1994), is in an inactive conformation in the cytosol 
until binding of EPO to the EPO-R activates a PTK, pre- 
sumably JAK2, that phosphorylates Y429 of the EPO-R 
and probably other substrates, possibly including Y431. 
Induction of Signaling Termination of Signaling 
Figure 7. BindingofSH-PTP1 totheTyrosine-Phosphorylated EPO-R 
Down-Modulates Signal Transduction by JAK2 
Abbreviation: P, phosphate group. 
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Engagement  of  the SH-PTP1 SH2 domain(s)  by the EPO-R 
both t rans locates  the phosphatase  to the receptor-  
s ignal ing complex  and act ivates  the phosphatase  activity 
in c lose prox imity  to poss ib le  substrates;  one  such sub- 
strate is JAK2.  The  t ime lag between assoc iat ion of SH- 
PTP1 with the EPO-R and return of  JAK2 phosphory la t ion  
to basa~l evels could  be caused  by act ivat ion or  inhibit ion of 
SH-PTP1 activity by other  downst ream s igna l - t ransduc ing 
molecules .  Dephosphory la t ion  of  JAK2 leads  to termina-  
t ion of  its s ignal ing capabi l i ty  and he lps  set the normal  
cel lu lar  level of  EPO sensit ivity. S ince a pY-conta in ing 
pept ide der ived f rom res idue Y429 of  the EPO-R specif i -  
cal ly act ivates SH-PTP1 and s ince overexpress ion  of SH- 
PTP1 represses  growth of a myelo id cell line, therapeut ic  
agents  mimick ing the activity mediated by this pY pept ide 
could be of therapeut ic  importance.  
Experimental Procedures 
Plasmids and Mutagenesis 
To convert yrosine residues to phenylalanines in the cytosolic domain 
of the EPO-R, point mutations were generated by overlap extension 
using the PCR with synthetic oligonucleotides encoding the desired 
amino acid substitutions (Higuchi et al., 1988). The C-terminal trun- 
cated EPO-R 1-374 was created by introducing an oligonucleotide 
that contained a stop codon into the Hindlll site at nucleotide position 
1221 in the EPO-R cDNA. Mutant EPO-R cDNAs were identified by 
sequencing using the dideoxynucleotide chain termination method 
and were subcloned into the eukaryotic expression vector pXM- 
EPO-R (D'Andrea et al., 1989; Longmore and Lodish, 1991) by ligating 
the ApaI-EcoRI fragment of the mutant EPO-R cDNAs into Apal- and 
EcoRI-cut pXM-EPO-R DNA. The construction of the C-terminal trun- 
cated EPO-R mutant (1-441) was described previously (Yoshimura et 
al., 1990b). 
Cell Culture and Transfections 
Wild-type or mutant EPO-R cDNAs in pXM were cotransfected with 
the selectable marker pRclCMV(neo) (Invitrogen) into the IL-3-depen- 
dent pro-B cell line Ba/F3 or into the myeloid cell line 32D by electro- 
potation, and stable cell lines were selected in G418 as described 
(Sk0da et al., 1993). To identify pools of transfected cells expressing 
an EPO-R, and thus competent o grow in the presence of EPO, neomy- 
cin-resistant colonies were transferred to medium containing 0.3 U of 
EPO/ml (Arris Pharmaceuticals) as the sole growth factor. EPO-respon- 
sive cell pools were further characterized by immunoprecipitation a d 
immunoblotting with anti-EPO-R antiserum. Cell pools that showed 
comparable surface expression of the wild-type or mutant EPO-Rs 
were identified by saturation binding of l~l-labeled EPO at 4°C (Hilton 
et al., 1988). IL-3-dependent and EPO-dependent cells were maintained 
as described previously (Yoshimura et al., 1990a). 
Immunoprecipitations and Immunoblotting 
Antibodies directed against the EPO-R were either raised against two 
peptides, corresponding to the N- and the C-termini of the EPO-R 
(an!i-N-EPO-R and anti-C-EPO-R; Yoshimura et al., 1990a), or against 
a GST-fusion protein containing the EPO-R extracellular domain (anti- 
EPO-R). The anti-EPO-R antiserum was affinity purified using the ex- 
tracellular domain of the EPO-R as a fusion protein, with the maltose- 
binding protein coupled to CN Br-activated Sepharose 4B (Pharmacia). 
Populations of Ba/F3 cells expressing wild-type or mutant EPO-Rs 
were washed with RPMI medium and were incubated at a density of 
5 x 107 cells/ml with 100 U of EPO/ml for the indicated times. Extracts 
were directly prepared by the addition of an equal volume of 2 x lysis 
buffer (2°/0 NP-40, 20% glycerol, 300 mM NaCI, 100 mM Tris-HCI [pH 
7.4], 100 mM NaF, 2 mM ZnCI2, 2 mM Na3VO4, 10 p.g/ml leupeptin, 
and 1 mM AEBSF [ICN Biomedicals]). For immunoprecipitations, the 
cell extracts (250 p.I) were incubated with 2 pg of affinity-purified poly- 
clonal rabbit antibodies against human SH-PTP1 (Lorenz et al., 1994), 
1 pl of JAK2 antiserum (Upstate Biotechnology), or 3 p.g of affinity- 
purified antibodies against the EPO-R, as indicated. Immune corn- 
plexes were recovered by binding to protein A-Sepharose beads 
(Boehringer Mannheim). Protein A-bound immunoprecipitates were 
washed three times with 1 x lysis buffer and once with TNE (50 mM 
Tris-HCI [pH 8.0], 150 mM NaCI, 1 mM Na3VO4, 1 mM ZnCI2, 1 mM 
EDTA), and they were eluted by boiling in SDS sample buffer. Samples 
were separated on 10% Iow-bis SDS-polyacrylamide gels, transferred 
to nitrocellulose membranes (Schleicher & SchQII), and incubated with 
the indicated antiserum in 150 mM NaCI, 10 mM Tris-HCI (pH 8.0), 
1% BSA, and 0.2% Tween-20 for 2 hr at room temperature. Antibodies 
used for immunoblotting were a polyclonal rabbit antiserum against 
SH-PTP1 (1 to 1000) (Lorenz et al., 1994), affinity-purified anti-EPO-R 
antiserum (1 to 5000), anti-C-EPO-R antiserum (1 to 1000), anti-JAK2 
antiserum (1 to 1000), and the monoclonal anti-PTyr antibody 4G10 
(anti-pTyr; 1 pg/ml). Bound antibodies were detected by incubation 
with horseradish peroxidase-coupled secondary antibodies (anti- 
rabbit or anti-mouse, as appropriate) (Amersham) and the enhanced 
chemiluminescence system (DuPont-NEN), as detailed by the manu- 
facturer. 
To reprobe immunoblots, filters were incubated in 62.5 mM Tris 
(pH 6.8) plus 0.1 M I~-mercaptoethanol plus 20/0 SDS for 30 rain at 
65°C and then were washed extensively in 10 mM Tris (pH 8) plus 
150 mM NaCI. 
GST-Fusion Proteins 
The N- and C-terminal SH2 domains of murine SH-PTP1 were cloned 
into the EcoRI site of the bacterial expression vector pGEX-2T (Phar- 
macia). For the N-terminal SH2 domain as well as for both of the SH2 
domains together (N-C), the cDNA fragments corresponding to amino 
acids 1-121 and 1-220, respectively, were amplified by PCR using 
Vent DNA polymerase (New England Biolabs). The amplified DNA 
fragments were sequenced by fluorescent dye technology on a 373A 
DNA sequencer (Applied Biosystems). E. coil transformants express- 
ing the GST-SH-PTP1 fusion proteins were induced with 0.5 mM IPTG 
(Sigma) at 30°C for 12 hr, harvested by centrifugation, and lysed as 
described previously (Songyang et al., 1993). Cells were stimulated 
with 100 U of EPO/ml for 5 rain at 37°C prior to detergent lysis. GST- 
fusion proteins bound to glutathione-agarose beads (approximately 
1 p.g of fusion protein per binding reaction) were incubated for 3 hr 
at 4°C with 250 pl of lysate, equivalent o 1 x 107 cells, in 1 x lysis 
buffer. After washing the beads several times with lysis buffer, ad- 
sorbed proteins were eluted and analyzed as described above for 
immunoprecipitates. 
Proliferation Assay 
Proliferation assays were performed in 96-well plates with 200 pl/well. 
Cells, at a concentration of 2 x 105 32D cells/ml, were seeded in the 
presence of indicated amounts of cytokines (EPO, 0-5 U/ml; IL-3, 
0-100 U/ml). After 48 hr, 1 pCi of [3H]thymidine/well (DuPont-NEN) 
was added for another 3 hr. The labeled cells were then harvested 
by a 96-well plate harvester (Scatron Instruments), and the amount 
of radioactively labeled DNA was quantitated in a scintillation counter. 
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